Small Molecules
16 November 2015
Janssen Presents New Data Assessing OLYSIO(R) (Simeprevir) in Combination with Sofosbuvir in Genotype 4 Infected HCV Patients In Egypt14 November 2015
TAGRISSO™ (AZD9291) approved by the US FDA for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer14 November 2015
Merck Provides Update on REVEAL Outcomes Study14 November 2015
Auven Therapeutics Announces Positive Results From Pivotal Clinical Trial of Seciera (OTX-101) in Dry Eye Disease14 November 2015
Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study13 November 2015
Concert Pharmaceuticals Initiates Phase 1 Multiple Ascending Dose Trial with CTP-656 for Cystic Fibrosis13 November 2015
PanOptica Reports Progress with PAN-90806, a Topical Anti-VEGF Eyedrop for the Treatment of Neovascular (Wet) AMD13 November 2015
Repros Therapeutics Completes Randomization of Phase 2b Study of Vaginal Proellex(R) in Women With Symptomatic Uterine Fibroid Bleeding13 November 2015
U.S. FDA Approves New Indications for Harvoni®, Gilead’s Once-Daily Single Tablet Regimen for Chronic Hepatitis C12 November 2015
FORUM Pharmaceuticals Inc. Announces Removal of Partial Clinical Hold on Phase 3 Encenicline Program for Cognitive Impairment in Schizophrenia12 November 2015
DeuteRx Presents DRX-065 for the Treatment of NASH at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)11 November 2015
CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis11 November 2015
FDA Approves Genentech’s Cotellic™ (Cobimetinib) in Combination With Zelboraf® (Vemurafenib) in Advanced Melanoma9 November 2015
Paratek Initiates Omadacycline Phase 3 Clinical Study in Community Acquired Bacterial Pneumonia (CABP)9 November 2015
Teva Announces Breakthrough Therapy Designation for SD-809 Granted by FDA for the Treatment of Tardive Dyskinesia9 November 2015
Collegium Announces FDA Tentative Approval for Xtampza(TM) ER, a Novel Abuse-Deterrent Analgesic for Chronic Pain9 November 2015
RedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines9 November 2015
BIND Presents Data Demonstrating Ability of Accurins to Improve Efficacy and Tolerability of Multiple Anti-Cancer Agents9 November 2015
Loxo Oncology TRK Inhibitor LOXO-101 Demonstrates Promising Clinical Activity and Safety in Phase 1 Trial9 November 2015
Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid TumorsNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports